Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
Shepherd, J., Brodin, H., Cave, C., Waugh, N., Price, A. and Gabbay, J. (2004) Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technology Assessment, 8, (39), 1-140.
Full text not available from this repository.
The aim of this systematic review and economic evaluation was to assess the clinical-effectiveness and cost-effectiveness of pegylated interferon-α combined with ribavirin in the treatment of chronic hepatitis C. The comparator was the current standard of treatment, non-pegylated interferon-α combined with ribavirin. Because some patients cannot tolerate ribavirin, treatment with pegylated interferon-α alone was also compared with treatment with non-pegylated interferon-α alone. Additional secondary questions were also addressed, including the effectiveness of retreating non-responders to interferon-α monotherapy, the use of non-invasive tests for gauging the severity of disease (e.g. fibrosis), and the effectiveness of antiviral treatment of patients with mild hepatitis C.
Epidemiology and background
Hepatitis C is a slowly progressive disease of the liver that is caused by infection with the hepatitis C virus (HCV). The virus can be transmitted in a number of ways, but the most common sources of infection are through injected drug use and infected blood products. Although some people infected with hepatitis C spontaneously clear the virus, up to 85% of those exposed develop chronic hepatitis. The rate of progression is slow and variable over 20–50 years. About 20–30% of those initially infected develop cirrhosis within 20 years and a small percentage of these are at high risk of hepatocellular carcinoma. Patients with chronic hepatitis C report diminished health-related quality of life, which can be improved by eradication of the virus. The prevalence of chronic hepatitis C in the UK is uncertain, but is estimated to be between 0.1 and 1%. Prevalence varies across different areas according to risk factors such as injecting drug use. Accurate prevalence rates are difficult to estimate because infection can remain asymptomatic for very long periods. There are several genotypes of the virus, the most common in England and Wales being 1a, 1b and 3a. Genotype 1 is harder to treat than genotypes 2 and 3.
Several electronic databases were searched including Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, Medline and Embase. Other sources searched included the reference lists of retrieved reports, and the industry submissions to the National Institute for Clinical Excellence (NICE). These searches revealed six studies that met the inclusion criteria of being randomised controlled trials (RCTs) involving comparisons between pegylated interferon-α plus ribavirin and non-pegylated interferon plus ribavirin (two trials) or pegylated interferon alone and non-pegylated interferon alone (four trials). The primary outcome in all trials was sustained virological response (SVR) at follow-up. The trials were generally of good quality, although reporting of methodological details could have been more thorough in places.
In the two trials that tested pegylated interferon plus ribavirin against non-pegylated interferon plus ribavirin the combined percentage of sustained virological response was 55% [95% (confidence interval (CI) 52–58%] when using pegylated interferon and 46% (95% CI 43–49%) for non-pegylated interferon.
When the two trials were meta-analysed the relative risk (RR) for remaining infected was reduced by 17% for pegylated interferon plus ribavirin compared with non-pegylated interferon plus ribavirin (RR 0.83, 95% CI 0.76 to 0.91).
Response to therapy varied according to viral genotype. Patients with genotype 1 had the lowest levels of sustained virological response (42% and 46% for pegylated interferon plus ribavirin in the two trials) and patients with genotype 2 or 3 had the highest levels of sustained virological response (82% and 76% for pegylated interferon plus ribavirin in the two trials).
There were also variations in sustained virological response according to other prognostic variables such as baseline viral load.
In the four trials that evaluated pegylated interferon monotherapy against non-pegylated interferon the combined sustained virological response rates were 31% (95% CI 27 to 34%) for pegylated interferon and 14% (95% CI 12 to 17%) for non-pegylated interferon.
The RR for remaining infected with hepatitis C was reduced by 20% with the use of pegylated interferon (RR 0.80, 95% CI 0.76 to 0.85).
As reported in three of the trials, response to therapy varied according to viral genotype. Patients with genotype 1 had the lowest levels of sustained virological response (12%, 14% and 31% for treatment with pegylated interferon in the three trials reporting response by genotype). Only one trial differentiated patients with non-1 genotypes and reported higher response rates in patients with genotype 4, 5, or 6 (60%) than in patients with genotype 2 or 3 (49%) when treated with pegylated interferon.
In the two trials that considered prognostic variables, there were also variations in sustained virological response according to other prognostic variables such as baseline viral load.
Regimens involving pegylated interferon appear to be fairly well tolerated. Adverse events were reported, but they did not differ substantially from levels of adverse events in regimens involving non-pegylated interferon.
A cost-effectiveness model originally developed by the Scottish Health Purchasing Information Centre and used in the previous NICE assessment report of treatment for hepatitis C was updated for the calculation of costs and benefits. The model followed a hypothetical cohort of 1000 individuals with chronic hepatitis C over a 30-year period. Options that were considered included: no treatment (except symptomatically), interferon-α plus ribavirin for 48 weeks, pegylated interferon-α plus ribavirin for 48 weeks, interferon monotherapy for 48 weeks, and pegylated interferon-α monotherapy for 48 weeks. SVRs from the key trials were pooled and entered into the model. The results were presented in terms of costs per quality-adjusted life-years (QALYs) gained.
The incremental discounted cost per QALY for comparing no active treatment to 48 weeks of dual therapy with pegylated interferon and ribavirin (PEG + RBV) is £6045. When moving from 48 weeks of dual therapy with non-pegylated interferon and ribavirin (IFN + RBV) to 48 weeks of dual therapy with PEG + RBV the figure is £12,123.
Subgroup analyses for dual PEG + RBV therapy demonstrated that the most favourable incremental discounted cost per QALY estimates were for patients infected with genotypes 2 and 3, and with low baseline viral load (£3921) compared with no active treatment.
Patients infected with genotype 1 and high baseline viral load had much higher estimates (£8305, no active treatment compared with dual therapy; £13,701, dual therapy with IFN compared with dual therapy with PEG).
Results of one-way sensitivity analyses showed that the estimates varied according to differences in SVRs, drug costs and discount rates. For example, when SVRs were increased or decreased in line with the highest and lowest limits of the confidence interval around the pooled SVR estimate, the highest discounted incremental cost per QALY was £37,611 (lowest PEG SVR and highest IFN SVR), compared with £7060 (highest PEG SVR and lowest IFN SVR).
In general estimates remained under £30,000 per QALY.
The incremental discounted cost per QALY when moving from no active treatment to 48 weeks of monotherapy with pegylated interferon was £6484. When moving from 48 weeks of monotherapy with IFN to 48 weeks of monotherapy with PEG the figure was £8404.
As with dual therapy, the lowest incremental cost per QALY was for patients with genotypes 2 and 3 and low baseline viral load, in the range £2641–4194. The highest estimates were for patients with genotype 1 and high baseline viral load, around £30,000.
A separate published meta-analysis of the two pivotal pegylated dual-therapy RCTs (not conducted by the authors of this report) found that excluding the 19% of patients who do not achieve early viral response at 12 weeks only misses 0.6% of potential responders. On the basis of these data it was recommended that only genotype 1 patients be assessed at week 12, with those not having an early viral response ceasing treatment, and those classed as having an early response completing the full 48 weeks of treatment, unless remaining HCV RNA positive at week 24, in which case they should stop treatment.
The following secondary questions were addressed.
Because treatment of hepatitis C is far from universally successful in eradicating the HCV, many patients remain infected after receiving treatment. Completed trials using pegylated interferon have not yet been reported in these patients, but published data on the efficacy of retreatment with non-pegylated interferon plus ribavirin compared with interferon alone are available. Meta-analysis of 20 of these trials found that SVR in retreatment was greater in patients given dual therapy than for those given monotherapy with interferon alone. The risk of remaining infected was reduced by 11% (RR 0.89, 95% CI 0.84 to 0.95) after 6 months of treatment (16 trials). The risk of remaining infected was reduced by 20% in two trials in which treatment was longer than 24 weeks (RR 0.80, 95% CI 0.66 to 0.96).
Because of the possibility that treating patients with acute hepatitis C infection might prevent chronic infection, treatment of patients with acute infection was briefly considered. Again, complete trials using pegylated interferon were not available. Trials in acute groups were of poorer methodological quality, but were suggestive that eradication rates much higher than spontaneous eradication are achievable with treatment.
Since many patients with hepatitis C have other co-morbidities such as co-infection with HIV or haemophilia, it was of interest to consider the efficacy of treatments within these patient groups. No fully published reports of trials using pegylated interferon were found. The existing evidence suggests that treatment efficacy in subpopulations with co-morbidities is generally similar to that in patient groups without significant co-morbidities. However, this does not necessarily mean that cost-effectiveness will be comparable, as this is based on estimating future disbenefits that would have occurred in the absence of treatment, which is sensitive to duration of survival, which in turn is influenced by the presence of co-morbidity.
Non-invasive tests have been proposed as an alternative to biopsy as a means of assessing fibrosis. The best indicators appear to be combinations or panels of tests, preferably those that are routinely available in clinics. They may be most useful at the ends of the spectrum; that is for identifying those with serious liver damage who would be treated, and those with mild disease who currently would not. For patients around the current treat/do not treat margin, the consensus is that liver biopsy is still often necessary, although the balance of risks is different in those with haemophilia.
Evidence on the effectiveness of treating patients with mild disease is awaited. If it can be demonstrated that treatment significantly improves quality of life for these patients then this could be an argument for treating all those with mild disease, without necessarily the need for liver biopsy. A reduction in quality of life has been reported in chronic infection, and if treatment with combined therapy restores quality of life to normal, it may be cost-effective on those grounds alone.
Well-designed RCTs show that patients treated with pegylated interferon, both as dual therapy and as monotherapy, experience higher sustained viral response rates than those treated with non-pegylated interferon. Patients with genotypes 2 and 3 experience the highest response, with rates in excess of 80%. Patients with the harder to treat genotype 1 nevertheless benefit, with up to 46% of patients experiencing an SVR in one of the trials. Pegylated interferon also appears to be relatively cost-effective in both monotherapy and dual therapy, with cost per QALY estimates remaining generally under £30,000. The most favourable estimates were for patients with genotypes 2 and 3.
|Keywords:||quality of life, model, quality-of-life, patients, therapies, viral load, genotype, outcomes, trial, review, plus ribavirin, report, drug costs, hepatitis c, randomized-trial|
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Community Clinical Sciences
University Structure - Pre August 2011 > School of Medicine > Medical Education
University Structure - Pre August 2011 > School of Medicine
|Date Deposited:||10 Sep 2008|
|Last Modified:||18 Aug 2012 03:02|
|Contributors:||Shepherd, J. (Author)
Brodin, H. (Author)
Cave, C. (Author)
Waugh, N. (Author)
Price, A. (Author)
Gabbay, J. (Author)
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)